Literature DB >> 26893688

Interleukin-8: A potent promoter of angiogenesis in gastric cancer.

Jun Shi1, Pin-Kang Wei1.   

Abstract

Angiogenesis is a critical process in the development of tumor malignancy and occurs at various stages of tumor progression. Interleukin-8 (IL-8) is a pro-angiogenic factor produced by tumor-infiltrating macrophages that has been revealed to facilitate the development of angiogenesis in various cancers. However, whether IL-8 activates angiogenesis in gastric cancer remains unclear. The present study investigated the effect of IL-8 on the migration and canalization capacities of human umbilical vein endothelial cells (HUVECs). In addition, the protein and messenger RNA (mRNA) expression of selected angiogenesis markers, consisting of vascular endothelial growth factor (VEGF)-A, VEGF receptor (VEGFR)-1 and VEGFR-2, were assessed in the HUVECs. The HUVECs were co-cultured with human gastric cancer SGC7901 cells and exposed to various concentrations of IL-8 (0, 0.2, 0.5, 0.8 and 1.0 ng/ml). The migration and canalization abilities of the cells were detected by Transwell chamber and tube formation assays. Protein expression was detected using immunofluorescence and western blot analysis, and mRNA levels were assessed using reverse transcription quantitative polymerase chain reaction. The protein and mRNA levels of VEGF-A, VEGFR-1 and VEGFR-2 were measured in HUVECs cultured for 24 h. IL-8 at concentrations of 0.5, 0.8 and 1.0 ng/ml significantly promoted HUVEC cell migration (P=0.005, P=0.001 and P<0.001, respectively) and tube formation (P=0.039, P=0.003 and P<0.001, respectively). IL-8 at concentrations of 0.2, 0.5, 0.8 and 1.0 ng/ml significantly elevated the protein levels of VEGF-A (P<0.001) and VEGFR-2 (P=0.034, P<0.001, P<0.001 and P<0.001, respectively). IL-8 at concentrations of 0.8 and 1.0 ng/ml significantly elevated the protein levels of VEGF-1 (P=0.037 and P=0.002, respectively). Similarly, IL-8 at concentrations of 0.5, 0.8 and 1.0 ng/ml significantly upregulated the mRNA levels of VEGF-A (P=0.046, P=0.001 and P<0.001, respectively) and VEGFR-1 (P=0.042, P<0.001 and P<0.001, respectively). IL-8 at concentrations of 0.2, 0.5, 0.8 and 1.0 ng/ml significantly upregulated the mRNA levels of VEGFR-2 (P=0.003, P=0.005, P<0.001 and P<0.001, respectively). In conclusion, IL-8 may be a potent promoter of angiogenesis in gastric cancer.

Entities:  

Keywords:  angiogenesis; gastric cancer; interleukin-8; vascular endothelial growth factor receptor-1; vascular endothelial growth factor receptor-2; vascular endothelial growth factor-A

Year:  2015        PMID: 26893688      PMCID: PMC4734231          DOI: 10.3892/ol.2015.4035

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  57 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of human gastric cancer cells.

Authors:  Wen-Xia Kuai; Qiong Wang; Xiao-Zhong Yang; Yao Zhao; Ren Yu; Xiao-Jun Tang
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 3.  Neuropilin signalling in angiogenesis.

Authors:  Sina Koch
Journal:  Biochem Soc Trans       Date:  2012-02       Impact factor: 5.407

Review 4.  Intussusceptive angiogenesis: a biologically relevant form of angiogenesis.

Authors:  Ward De Spiegelaere; Christophe Casteleyn; Wim Van den Broeck; Johanna Plendl; Mahtab Bahramsoltani; Paul Simoens; Valentin Djonov; Pieter Cornillie
Journal:  J Vasc Res       Date:  2012-06-26       Impact factor: 1.934

5.  Interleukin-8 is associated with adhesion, migration and invasion in human gastric cancer SCG-7901 cells.

Authors:  Dawei Ju; Dazhi Sun; Lijuan Xiu; Xianze Meng; Cian Zhang; Pinkang Wei
Journal:  Med Oncol       Date:  2010-12-30       Impact factor: 3.064

6.  Interleukin-8 as a macrophage-derived mediator of angiogenesis.

Authors:  A E Koch; P J Polverini; S L Kunkel; L A Harlow; L A DiPietro; V M Elner; S G Elner; R M Strieter
Journal:  Science       Date:  1992-12-11       Impact factor: 47.728

Review 7.  Angiogenesis: an organizing principle for drug discovery?

Authors:  Judah Folkman
Journal:  Nat Rev Drug Discov       Date:  2007-04       Impact factor: 84.694

Review 8.  Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders.

Authors:  Aernout Luttun; Marc Tjwa; Peter Carmeliet
Journal:  Ann N Y Acad Sci       Date:  2002-12       Impact factor: 5.691

Review 9.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

Review 10.  Molecular mechanisms of lymphangiogenesis in health and disease.

Authors:  Kari Alitalo; Peter Carmeliet
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

View more
  29 in total

Review 1.  Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.

Authors:  Charli Dominguez; Justin M David; Claudia Palena
Journal:  Semin Cancer Biol       Date:  2017-08-18       Impact factor: 15.707

Review 2.  Dysregulation of TTP and HuR plays an important role in cancers.

Authors:  Hao Wang; Nannan Ding; Jian Guo; Jiazeng Xia; Yulan Ruan
Journal:  Tumour Biol       Date:  2016-09-19

3.  Matricellular protein SPARCL1 regulates tumor microenvironment-dependent endothelial cell heterogeneity in colorectal carcinoma.

Authors:  Elisabeth Naschberger; Andrea Liebl; Vera S Schellerer; Manuela Schütz; Nathalie Britzen-Laurent; Patrick Kölbel; Ute Schaal; Lisa Haep; Daniela Regensburger; Thomas Wittmann; Ludger Klein-Hitpass; Tilman T Rau; Barbara Dietel; Valérie S Méniel; Alan R Clarke; Susanne Merkel; Roland S Croner; Werner Hohenberger; Michael Stürzl
Journal:  J Clin Invest       Date:  2016-10-10       Impact factor: 14.808

4.  PRSS21/testisin inhibits ovarian tumor metastasis and antagonizes proangiogenic angiopoietins ANG2 and ANGPTL4.

Authors:  Gregory D Conway; Marguerite S Buzza; Erik W Martin; Nadire Duru; Tierra A Johnson; Raymond J Peroutka; Nisha R Pawar; Toni M Antalis
Journal:  J Mol Med (Berl)       Date:  2019-03-25       Impact factor: 4.599

Review 5.  Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation.

Authors:  Julia Kzhyshkowska; Alexandru Gudima; Kondaiah Moganti; Alexei Gratchev; Alexander Orekhov
Journal:  Transfus Med Hemother       Date:  2016-03-15       Impact factor: 3.747

Review 6.  PharmGKB summary: pazopanib pathway, pharmacokinetics.

Authors:  Caroline F Thorn; Manish R Sharma; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-08       Impact factor: 2.089

Review 7.  Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.

Authors:  Henrik Nienhüser; Thomas Schmidt
Journal:  Int J Mol Sci       Date:  2017-12-23       Impact factor: 5.923

8.  CXCL8 derived from tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression by promoting migration and invasion of cancer cells.

Authors:  Masayoshi Hosono; Yu-Ichiro Koma; Nobuhisa Takase; Naoki Urakawa; Nobuhide Higashino; Kazuki Suemune; Himiko Kodaira; Mari Nishio; Manabu Shigeoka; Yoshihiro Kakeji; Hiroshi Yokozaki
Journal:  Oncotarget       Date:  2017-11-20

9.  High-mobility group box-1 contributes tumor angiogenesis under interleukin-8 mediation during gastric cancer progression.

Authors:  Hye Won Chung; Jong-Baeck Lim
Journal:  Cancer Sci       Date:  2017-07-07       Impact factor: 6.716

10.  IL-6 trans-Signaling Impairs Sprouting Angiogenesis by Inhibiting Migration, Proliferation and Tube Formation of Human Endothelial Cells.

Authors:  Mulugeta M Zegeye; Blanka Andersson; Allan Sirsjö; Liza U Ljungberg
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.